What is Nasus Pharma?
Nasus Pharma is at the forefront of pharmaceutical innovation, specializing in the development of a diverse portfolio of powder-based intranasal products. These products are engineered to address acute medical conditions and public health emergencies, leveraging proprietary microsphere technology for rapid absorption and swift drug delivery. The company's intranasal therapies, including critical treatments like Naloxone and Epinephrine, are designed for maximum speed and efficacy in life-saving scenarios. Nasus Pharma targets healthcare providers and emergency response systems that demand highly efficient drug delivery solutions during critical moments.
How much funding has Nasus Pharma raised?
Nasus Pharma has raised a total of $15M across 1 funding round:
Private Equity
$15M
Private Equity (2026): $15M, investors not publicly disclosed
What's next for Nasus Pharma?
The substantial enterprise-level funding and recent strategic investment position Nasus Pharma for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand the commercialization of their life-saving intranasal therapies. The company's focus on rapid drug delivery for acute conditions aligns with increasing demand for efficient emergency medical solutions, suggesting a strong trajectory for market leadership in this specialized pharmaceutical sector.
See full Nasus Pharma company page
